Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association of Plasma PTX3 Concentration and Outcomes of STEMI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03894176
Recruitment Status : Completed
First Posted : March 28, 2019
Last Update Posted : March 28, 2019
Sponsor:
Information provided by (Responsible Party):
Surya Dharma, Indonesian Cardiovascular Research Center

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method. The angiographic and clinical outcomes were evaluated according to the PTX3 concentration.

Condition or disease Intervention/treatment
STEMI Coronary; Ischemic Other: Plasma PTX3 concentration

Detailed Description:
335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method using human PTX3 kit. Blood was drawn at the emergency department before primary PCI. The angiographic and clinical outcomes were evaluated and analyzed according to the PTX3 concentration. The angiographic outcome were thrombus grade on initial angiogram and final TIMI flow. The clinical outcome were ECG resolution after primary PCI and all-cause death at 30 days. The plasma PTX3 concentration was then compared based on the outcomes.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 335 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Association of Plasma Pentraxin 3 Concentration With Angiographic and Clinical Outcomes in STEMI Treated by Primary Angioplasty
Actual Study Start Date : January 1, 2018
Actual Primary Completion Date : August 2, 2018
Actual Study Completion Date : September 2, 2018
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
PTX3 concentration
First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
 Other: Plasma PTX3 concentration
Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
Other Name: PTX3


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The proportion of thrombus grade 4&5 and final TIMI flow <3 [ Time Frame: Intraprocedure ]
    PTX3 concentration was compared based on the outcome


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with STEMI with symptom onset <12 h who admiited to the emergency department and planned for primary PCI.
Criteria

Inclusion Criteria:

  • Patients with acute STEMI with symptom onset <12 h undergoing primary PCI

Exclusion Criteria:

  • Acute STEMI patients who received fibrinolytic therapy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03894176


Locations
Layout table for location information
Indonesia
Indonesian Cardiovascular Research Center
Jakarta, DKI Jakarta, Indonesia, 11420
Sponsors and Collaborators
Indonesian Cardiovascular Research Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Surya Dharma, Primary Investigator, Indonesian Cardiovascular Research Center
ClinicalTrials.gov Identifier: NCT03894176    
Other Study ID Numbers: IndonesianCRC
First Posted: March 28, 2019    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
ST Elevation Myocardial Infarction
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
 Vascular Diseases
Infarction
Ischemia
Pathologic Processes
Necrosis